In anticipation of its presentation at the J.P. Morgan Global Healthcare Conference, obesity drugmaker VIVUS (VVUS) released its presentation in an SEC filing. Investors were particularly impressed with the improved prescription data for Qsymia, and shares jumped around 8% today on this news. In the following video, health care analyst Max Macaluso discusses this news, reasons for why Qsymia prescriptions are gaining momentum, and what this means for Arena Pharmaceuticals (ARNA) -- VIVUS' main competitor in the obesity drug market.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.